1093306-91-2

Upstream product

• 1093306-90-1 N-methoxy-N-methyl-1H-indazole-5-carboxamide 
• 6921-34-2 benzylmagnesium chloride 
• 61700-61-6 1H-indazole-5-carboxylic acid 

Downstream Products

• 1093306-92-3 tert-butyl 5-(2-phenylacetyl)-1H-indazole-1-carboxylate 
• 1093306-93-4 2-bromo-1-(1H-indazol-5-yl)-2-phenylethanone 
• 1093303-23-1 2-(1H-indazol-5-yl)-3-phenylimidazo[1,2-a]pyrimidine 
• 1093303-19-5 4-(1H-indazol-5-yl)-N,5-diphenyl-1,3-thiazol-2-amine 
• 1093303-17-3 C₂₃H₁₈N₄S 

Relevant academic research and scientific papers

Scaffold oriented synthesis. Part 4: Design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing heterocycle forming and multicomponent reactions

We report the synthesis and biological evaluation of 5-substituted indazoles as kinase inhibitors. The compounds were synthesized in a parallel synthesis fashion from readily available starting materials employing heterocycle forming and multicomponent reactions and were evaluated against a panel of kinase assays. Potent inhibitors were identified for Gsk3β, Rock2, and Egfr.

5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.